How the U.K. is reacting to King Charles' visit to the U.S.

NPR | By Steve Inskeep

Published April 29, 2026 at 4:36 AM EDT

NPR's Steve Inskeep speaks with Lord Peter Ricketts, a member of the House of Lords and a former British diplomat, about King Charles' visit to the U.S. during a tumultuous time.

NPR News

Steve Inskeep

Steve Inskeep is a host of NPR's Morning Edition, as well as NPR's morning news podcast Up First.

See stories by Steve Inskeep

Support nonprofit, fact-based public service journalism

WEKU depends on support from those who view and listen to our content. There's no paywall here. Please support WEKU with your donation.

Contribute now

Related Content

Texas' hemp industry fights new regulations that have upended the legal hemp market

Nathan Bernier

One of the country's largest legal cannabis markets is fighting for its life. Texas' hemp industry is challenging fee increases of up to 4,000%, which effectively ban cannabis' most popular form.
NPR News

RFK Jr. wants to treat addiction by creating wellness farms. Does it work?

Brian Mann

U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. says a farm community in Italy for people with addiction is a model for wellness camps designed to ease the U.S. overdose crisis. Critics say the idea is dangerous.
NPR News

Supreme Court weighs Trump's effort to end Temporary Protected Status for Haitians, Syrians

Nina Totenberg

At issue is the TPS program, which permits eligible individuals to live and work in the United States if they cannot return to their home countries because of "extraordinary or temporary conditions."
NPR News

How a Republican state lawmaker tried to let Holocaust deniers hijack history lessons

Tom Dreisbach

A New Hampshire Republican. A German Holocaust denier. A suspicious bottle of baby oil. An NPR investigation reveals how the alarming rise of antisemitic conspiracy theories reached a state capitol.
NPR News

How a Supreme Court fight over fish oil could raise your prescription drug costs

Leslie Walker

The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the way generic companies do business.